Medical devices, healthcare technology and the business of care
510(k) clearance · K261759

Euphora Rapid Exchange (RX) Balloon Dilatation Catheter

Medtronic Ireland · Decision date Jul 27, 2026

FDA DECISIONK261759

What did the FDA decide?

FDA records K261759 as a 510(k) premarket notification, with a decision dated Jul 27, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Jul 27, 2026

FDA source record

Regulatory record facts

Identifier
K261759
Regulatory pathway
510(k) premarket notification
Product code
LOX
Decision code
SESE
Decision date
Jul 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheters, Transluminal Coronary Angioplasty, Percutaneous.

Product code
LOX
FDA device class
2

FDA decision timeline

  1. K261759 received

    Application receipt date recorded by FDA.

  2. K261759 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LOX

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Ireland510(k) clearanceAug 14, 2026FDA
Shanghai MicroPort Medical (Group) Co., Ltd.510(k) clearanceApr 7, 2026FDA
Verge Medical, Inc.510(k) clearanceApr 2, 2026FDA
RyureiK252295
Terumo Corporation510(k) clearanceMar 27, 2026FDA
Medtronic Ireland510(k) clearanceJan 17, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Ireland

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
Galway

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records